Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 751 - 775 of 8198 in total
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in...
Approved
Investigational
Matched Description: … the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Approved
Matched Description: … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes …
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Description: … Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. ... Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus …
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational
Matched Description: … Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia ... Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of ... It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake …
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted...
Approved
Investigational
Matched Description: … inhibition of immune responses seen in some cancers. ... The rest of atezolizumab indications remain unaffected.[L44246] ... Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing …
Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).
Approved
Investigational
Matched Description: … Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms …
A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed)
Approved
Matched Description: … A homolog of ergonovine containing one more CH2 group. (Merck Index, 11th ed) …
A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Approved
Matched Description: … and subcortical areas of the brain. ... It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord …
Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the body. Miglitol should be taken at the start...
Approved
Matched Description: … amount of poly and oligosaccharides in the diet. ... used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of ... Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the …
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Approved
Investigational
Matched Description: … A potent inhibitor of adenosine deaminase. ... The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell …
An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also...
Approved
Matched Description: … prevention of duodenal ulcer recurrence. ... It also potentiates the effect of other antiulcer agents such as cimetidine and ranitidine. ... It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the …
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Approved
Investigational
Matched Description: … Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors …
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Approved
Matched Description: … inhibits the late phase of protein synthesis. ... Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections ... Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin …
Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
Approved
Investigational
Matched Description: … Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension. …
Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate. It is indicated for treatment of endogenous anterior uveiti.
Approved
Matched Description: … It is indicated for treatment of endogenous anterior uveiti. ... It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. ... Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated …
Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli. It received European Union Approval in July 2017 for the treatment of moderate to severe neurotrophic keratitis. Cenegermin received approval from the US FDA a year later in August of 2018. Neurotrophic keratitis is a...
Approved
Investigational
Matched Description: … The loss of corneal sensation impairs corneal health, causing progressive damage to the top layer of ... [L4563] While the prevalence of neurotrophic keratitis is low, the impact of this serious condition ... the treatment, diagnosis or prevention of a serious condition. …
A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.
Approved
Investigational
A pyrethroid insecticide commonly used in the treatment of lice infestations and scabies. It is a yellow to light orange-brown, low melt-ing solid or viscous liquid.
Approved
Investigational
Matched Description: … A pyrethroid insecticide commonly used in the treatment of lice infestations and scabies. …
Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved
Methenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane. In salt form it is used for the treatment of urinary tract infection (Example: methenamine hippurate which is the hippuric acid salt of methenamine).
Approved
Vet approved
Matched Description: … which is the hippuric acid salt of methenamine). ... In salt form it is used for the treatment of urinary tract infection (Example: methenamine hippurate …
Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for high affinity binding...
Approved
Matched Description: … This complex greatly accelerates the inhibition of factor Xa. ... It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. ... Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated …
Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow...
Approved
Vet approved
Matched Description: … Higher level of oxygen than ambient air (hyperoxia) can be introduced under normobaric or hyperbaric ... Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing …
Padimate O is an active sunscreen agent in cosmetics and over-the-counter sunscreen drug products in concentrations up to 8%, as regulated by the FDA . It is a structurally-related compound to DB02362 that absorbs UV-B rays to prevent photodamage. It penetrates human skin, and is shown to induce non-ligatable strand...
Approved
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Approved
Investigational
Vet approved
Matched Description: … Griseofulvin may be given by mouth in the treatment of tinea infections. …
Sotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of...
Approved
Investigational
Matched Description: … 2021, based on interim results from a clinical trial, where sotrovimab was found to reduce the risk of
Displaying drugs 751 - 775 of 8198 in total